Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
about
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyLife-threatening complications following multidose methotrexate for medical management of ectopic pregnancyInfluence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia.Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review.Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han populationBetween-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.Pharmacogenetics of childhood acute lymphoblastic leukemia.A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation - review of literature.Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis.Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.Clinically relevant pharmacogenomic testing in pediatric practice.MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapseInfluence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate.Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis.Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.
P2860
Q28083449-611839B3-A6AC-4C5B-8766-DF883D680284Q33402976-9668BE87-CBA4-47FF-98D6-3A355489A963Q33716494-10B6A73C-95DE-4D80-9957-EC8E942CC73AQ34336668-1EB0A304-461D-4FA2-AC5E-7C85D8B21C76Q36681506-F5BD602D-4B41-4EE9-A85D-5D4A5198F62AQ37034349-CD9D5734-9EC1-4996-83D8-44D31B1FA78CQ38054428-FCC6DC75-5982-4488-BF2D-5177C2669F93Q38063197-EC3C059F-F66C-4D12-ABB7-D4B517AB766CQ38243175-B47EAC37-C312-4D86-923F-EB2318988C3AQ38384376-0723D0D6-D2B7-4C23-B7C3-2CE9CF26284DQ38416696-87AE618E-B2D1-4A1D-BF53-094FAB193871Q38506522-5A5207B0-CF0F-44E7-90F6-EF4828F81A42Q38824755-E5AB2FCE-2373-4135-AE5F-816F8CD11B64Q38895172-37942C06-040B-4EB1-8DF8-3E87336F7725Q39197183-26E20EC9-2EF3-4197-A970-298066468A8EQ39230513-B5E7F286-52CE-40BE-9D02-9CD1455D7B9CQ42115117-279167F7-D139-45AC-BC38-54AB32058BF0Q43661173-A33047B2-2B36-4D13-9DAF-A0B20790F0EEQ43716583-A92C442D-B66F-4282-AAC4-611A0A65E8D6Q44063364-E7CF27A7-8BB2-4B8C-9619-9D6393125E73Q47985415-C59334DE-FFD4-4E82-A150-12BADC664780Q48331843-6E236933-457A-4842-8C03-DBA32F6AC798Q53581480-A1225334-CB4A-4A9E-B120-171017A56245
P2860
Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@en
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@nl
type
label
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@en
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@nl
prefLabel
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@en
Methotrexate toxicity and effi ...... pharmacogenetic determinants.
@nl
P2093
P2860
P1476
Methotrexate toxicity and effi ...... s pharmacogenetic determinants
@en
P2093
Addolorata Napolitano
Adriana Iannotta
Claudia Fusco
Cristiana Indolfi
Fiorina Casale
Giulia Pecoraro
Maria Carmen Affinita
Maria Ramaglia
Matilde Oreste
Matteo Francese
P2860
P2888
P304
P356
10.1007/S00280-011-1665-1
P577
2011-05-18T00:00:00Z